Episode 15: Sayeh Nikpay – From Safety Net to Profit Center: The Complicated Truth About the 340B Program
In this episode, hosts Stephen Parente and Thom Gunderson explore the complexities of the 340B drug pricing program, its origins,
Episode 14: Rena Conti, Marta Wosinska, and Doug Holtz-Eakin – TrumpRx, Medicaid Cuts, and the Future of Drug Pricing
In this episode of On Background, host Stephen Parente conducts a roundtable with previous guests Marta Wosinska, Rena Conti, and
Episode 13: Kenny White – The Complexities of the US Health Insurance Industry
In this episode of On Background, we talk with Kenny White and explore the complexities of the US health insurance
Episode 12: 2025 Year in Review – Health Policy Highlights and What’s Ahead in 2026
In this year-end review, hosts Stephen Parente, Thom Gunderson, and Matt Stoll discuss key topics covered throughout 2025 in the
Episode 11: CHES 2025 Roundtable – The Health Data Wish List: What Economists Need to Fix US Health Policy
In this episode of On Background, host Stephen Parente leads a conversation around the challenges and opportunities in health economic
Episode 10: Eric Hargan – Affordable Care Act Subsidies and The State of Play for Healthcare Policy in Washington
In this episode of the On Background podcast, host Steve Parente and former Deputy Secretary of HHS Eric Hargan discuss
Episode 9: Rena Conti – The 340B Problem: When a Safety Net Program Loses Its Way
In this episode, the discussion revolves around the 340B Drug Pricing Program, its origins, current issues, and potential reforms. Rena
Episode 8: Joe Antos – The Impact of Employer-Sponsored Insurance on Market Competition, Drug Pricing, and the Evolution of Payment Mechanisms.
In this episode of On Background, health policy professionals discuss the complexities of healthcare costs, innovations, and the evolution of
Episode 7: Marta Wosinka – Generic Drugs, Global Supply Chains, and the Limits of FDA Oversight
In this episode, Marta Wosinska discusses the complexities of pharmaceutical quality oversight, focusing on the roles of the FDA and









